Lichtenstein DA BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. Chest. 2015 Jun;147(6):1659-1670. doi: 10.1378/chest.14-1313. Review.
Matics TJ, Sanchez-Pinto LN Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. JAMA Pediatr. 2017 Oct 2;171(10):e172352. doi: 10.1001/jamapediatrics.2017.2352. Epub 2017 Oct 2.
Mojoli F, Bouhemad B, Mongodi S, Lichtenstein D Lung Ultrasound for Critically Ill Patients. Am J Respir Crit Care Med. 2019 Mar 15;199(6):701-714. doi: 10.1164/rccm.201802-0236CI. Review. Erratum in: Am J Respir Crit Care Med. 2020 Apr 15;201(8):1015. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1454.
Morris JV, Ramnarayan P, Parslow RC, Fleming SJ Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study. Crit Care Med. 2017 Jun;45(6):1045-1053. doi: 10.1097/CCM.0000000000002369.
Payen V, Jouvet P, Lacroix J, Ducruet T, Gauvin F Risk factors associated with increased length of mechanical ventilation in children. Pediatr Crit Care Med. 2012 Mar;13(2):152-7. doi: 10.1097/PCC.0b013e3182257a24.
Senna S, Ong C, Wong JJ, Allen JC Jr, Sultana R, Lee JH Prediction of Acquired Morbidity Using Illness Severity Indices in Pediatric Intensive Care Patients. Pediatr Crit Care Med. 2020 Nov;21(11):e972-e980. doi: 10.1097/PCC.0000000000002417.
Zong HF, Guo G, Liu J, Bao LL, Yang CZ Using lung ultrasound to quantitatively evaluate pulmonary water content. Pediatr Pulmonol. 2020 Mar;55(3):729-739. doi: 10.1002/ppul.24635. Epub 2020 Jan 9.
Lung Ultrasound Score and Pediatric Intensive Care Outcomes: a Prospective Observational Multicenter Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.